Plain-English translation of NCT06285643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This Phase 2 trial is testing a new gene therapy called AAV2-GDNF that is delivered directly into a specific part of the brain (the putamen) through surgery. The goal is to see whether this treatment can help reduce symptoms in people with moderate Parkinson's disease and improve their quality of life. About half of participants will receive the active treatment while the other half will receive a sham (placebo) surgery so researchers can fairly measure how well the medication works.
Parkinson's disease causes progressive loss of nerve cells and currently available medications become less effective over time. This trial is exploring whether directly delivering a gene therapy to the brain can help protect or restore nerve cells and provide longer-lasting symptom relief than current treatments alone.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have brain surgery where doctors inject the gene therapy (or placebo) into a specific region of your brain. You will be randomly assigned to receive either the active treatment or the sham surgery, and neither you nor the researchers will know which you received. After surgery, you will have multiple follow-up visits over the course of the study to assess your symptoms, safety, and how well the treatment is working.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States